Caribou Biosciences (CRBU) Receivables (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Receivables data on file, last reported at $1.7 million in Q1 2026.

• Receivables for Q1 2026 came in at $1.7 million, down 13.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 million (down 13.46% YoY), and the FY2025 annual result was $2.0 million, down 5.73% from the prior year.
• Receivables fell to $1.7 million in Q1 2026 per CRBU's latest filing, from $2.0 million in the prior quarter.
• Over five years, Receivables peaked at $3.6 million in Q2 2022 and troughed at $1.7 million in Q1 2026.
• A 5-year average of $2.4 million and a median of $2.1 million in 2024 frame the typical range for Receivables.
• The sharpest annual moves came in 2022 and 2023: Receivables slumped 63.58% in 2022, then soared 71.47% in 2023.
• A 5-year view of Receivables shows it stood at $2.4 million in 2022, then increased by 0.7% to $2.4 million in 2023, then retreated by 14.01% to $2.1 million in 2024, then retreated by 5.73% to $2.0 million in 2025, then decreased by 15.26% to $1.7 million in 2026.
• Business Quant data shows CRBU's Receivables at $1.7 million in Q1 2026, $2.0 million in Q4 2025, and $2.1 million in Q3 2025.